Leptin

Leptin binds LepR (JAK2-associated cytokine receptor) on arcuate nucleus neurons, activating JAK2 phosphorylation of STAT3, which translocates to the nucleus and activates POMC and CART gene expression while repressing NPY/AgRP. The net hypothalamic effect is reduced appetite, increased metabolic rate, and altered fuel partitioning toward fat oxidation. LepR is also expressed in the ventromedial hypothalamus, lateral hypothalamus, and brainstem, coordinating broad aspects of energy balance. Beyond appetite, leptin regulates immune function (promoting Th1 responses), bone metabolism, reproductive function (leptin deficiency causes hypogonadotropic hypogonadism), and glucose metabolism.

In most common obesity, leptin signaling is blunted despite hyperleptinemia. Key resistance mechanisms: (1) Defective leptin transport across the blood-brain barrier (reduced expression of tanycyte transporters); (2) Increased SOCS3 (suppressor of cytokine signaling-3) expression, which attenuates JAK-STAT signaling; (3) Endoplasmic reticulum stress in hypothalamic neurons impairing LepR trafficking; (4) Inflammatory signaling (IKK-beta, JNK) in the mediobasal hypothalamus interfering with leptin signal transduction. Strategies to overcome leptin resistance, rather than simply increasing leptin dose - are the focus of current obesity pharmacology research.

Beyond the hypothalamus, leptin receptors are expressed in the liver, pancreas, heart, and immune cells. In the liver, leptin promotes fatty acid oxidation and reduces triglyceride synthesis, relevant to non-alcoholic fatty liver disease (NAFLD). In pancreatic beta-cells, leptin reduces insulin secretion, providing a feedback circuit between adiposity and insulin levels. In the cardiovascular system, leptin has complex effects, it promotes sympathetic activity (raising blood pressure and heart rate) and promotes oxidative stress in vascular cells, potentially contributing to the elevated cardiovascular risk in obesity.

Metreleptin (Myalept) is FDA-approved for congenital leptin deficiency (a rare recessive condition) and generalized lipodystrophy. In leptin-deficient patients, metreleptin produces dramatic weight loss (20-50% reduction in body weight), normalized reproductive function, improved insulin sensitivity, and reduced liver fat. In lipodystrophy (where absent adipose tissue causes near-zero leptin levels despite metabolic dysfunction), metreleptin significantly improves severe insulin resistance, hyperlipidemia, and liver disease.

The Ravussin et al studies (2009, Obesity) showed that leptin combined with amylin/" class="wiki-internal-link">amylin produced 12-13% weight loss versus 8% for amylin alone and 3% for leptin alone in obese patients, a landmark demonstration that combining the two hormones overcomes leptin resistance. Amylin appears to restore central leptin responsiveness, possibly by reducing hypothalamic inflammation or directly modulating LepR signaling. This synergy has driven pharmaceutical development of amylin-leptin combinations.

Exogenous leptin replacement has clear benefit in states of true hypoleptinemia. In female athletes with functional hypothalamic amenorrhea (disrupted menstrual cycles due to energy restriction-induced low leptin), metreleptin treatment restores LH pulsatility and menstrual function. In anorexia nervosa, where leptin is critically low, leptin signaling disruption contributes to bone loss, immune dysfunction, and hypothalamic suppression. Replacement in these contexts, rather than in obesity where leptin resistance is the problem - represents a rational therapeutic approach.